Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anokion Announces Positive Phase 2 Data for KAN-101 in Celiac Disease
Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 08, 2025
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anokion Announces Early Completion of Enrollment in KAN-101 Trials for Celiac Disease
Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2024
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anokion Announces New Clinical Data of KAN-101 for the Treatment of Celiac Disease
Details : KAN-101 is a novel immune tolerance therapy for the treatment of celiac disease. The ongoing ACeD-it and SynCeD global clinical trials continue to demonstrate favourable safety and efficacy data.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Anokion Announces Clinical Progress with KAN-101 and ANK-700
Details : KAN-101 is a novel immune tolerance therapy, which encompasses an established gluten antigen delivered to the liver and immune system using the company’s proprietary liver-targeting technology.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2023
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ESO-101 (mometasone furoate), designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition, has the potential to provide significant clinical benefits to eos...
Product Name : ESO-101
Product Type : Steroid
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EsoCap Completes Patient Recruitment in ACESO Phase II Trial in Eosinophilic Esophagitis
Details : ESO-101 was designed as a locoregional, esophagus-adjusted drug formulation and novel delivery system to optimize mucosal contact time and maximize esophageal deposition of mometasone furoate. it has the potential to provide significant clinical benefits...
Product Name : ESO-101
Product Type : Steroid
Upfront Cash : Inapplicable
May 09, 2023
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Esocap Holds a Multidisciplinary Advisory Board Meeting on Barrett's Esophagus
Details : ESO-101 (Mometasone Furoate), EsoCap’s lead product candidate, consists of a capsule with a rolled, thin mucoadhesive film, loaded with the anti-inflammatory corticosteroid, mometasone furoate.
Product Name : ESO-101
Product Type : Steroid
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Mometasone Furoate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vibegron
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vibegron was very well tolerated in the study and did not lead to any worsening of IBS symptoms. Key secondary endpoint of Global Improvement Scale (GIS) showed numerical differences in favor of vibegron versus placebo, however data was not statistically...
Product Name : Gemtesa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : Vibegron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Surveyor Capital
Deal Size : $110.0 million
Deal Type : Financing
Details : Proceeds will fund the Phase III program of apraglutide, a potential best-in-class GLP-2 analog, as well as global commercialization and business development activities.
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Undisclosed
October 15, 2020
Lead Product(s) : Apraglutide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Surveyor Capital
Deal Size : $110.0 million
Deal Type : Financing